Table 1.
Clinical and immunological data of subjects included in the study.
| ZCL patients (n = 15) | Healed ZCL subjects (n = 24) | Healthy subjects living in endemic area (n = 11) | Healthy subjects living outside endemic area (n = 9) | |
|---|---|---|---|---|
| Age, mean ± SD (min-max), year | 11.5 ± 2.5 (7–16) |
13.7 ± 1.16 (12–16) |
13.45 ± 1.57 (11–16) |
24.78 ± 4.29 (20–30) |
| Male/Female | 6/9 | 10/14 | 6/5 | 6/3 |
| Number of lesion, mean (min-max) | 2,6 (1–7) | 0 | 0 | 0 |
| ZCL scara | 0/15 | 24/24 | 0 | 0 |
| LSTb Induration's diameter, mean ± SD (min-max), mm | 10/11 7.6 ± 3.1 (0–15) | 22/22 10.22 ± 2.5 (5.5–15.5) | 0/11 0 | ND |
| Leishmania-specific lymphoproliferative responsec | 8/9 | 20/23 | 1/9 | 0/9 |
LST, Leishmanin Skin Test; ZCL, Zoonotic Cutaneous Leishmaniasis; ND, Not done.
a
Number of subject with ZCL scar/Total number of subject tested.
b
Number of subject with positive LST/Total number of subject tested.
Positive LST, Induration's diameter ≥5 mm.
c
Number of subject with positive Leishmania-specific lymphoproliferative response (Δcpm ≥ 5,000)/Total number of subject tested.